↓ Skip to main content

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

Overview of attention for article published in European Urology, January 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

blogs
1 blog
twitter
17 X users
f1000
1 research highlight platform

Citations

dimensions_citation
204 Dimensions

Readers on

mendeley
308 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Published in
European Urology, January 2014
DOI 10.1016/j.eururo.2014.01.003
Pubmed ID
Authors

Elizabeth K. Bancroft, Elizabeth C. Page, Elena Castro, Hans Lilja, Andrew Vickers, Daniel Sjoberg, Melissa Assel, Christopher S. Foster, Gillian Mitchell, Kate Drew, Lovise Mæhle, Karol Axcrona, D. Gareth Evans, Barbara Bulman, Diana Eccles, Donna McBride, Christi van Asperen, Hans Vasen, Lambertus A. Kiemeney, Janneke Ringelberg, Cezary Cybulski, Dominika Wokolorczyk, Christina Selkirk, Peter J. Hulick, Anders Bojesen, Anne-Bine Skytte, Jimmy Lam, Louise Taylor, Rogier Oldenburg, Ruben Cremers, Gerald Verhaegh, Wendy A. van Zelst-Stams, Jan C. Oosterwijk, Ignacio Blanco, Monica Salinas, Jackie Cook, Derek J. Rosario, Saundra Buys, Tom Conner, Margreet G. Ausems, Kai-ren Ong, Jonathan Hoffman, Susan Domchek, Jacquelyn Powers, Manuel R. Teixeira, Sofia Maia, William D. Foulkes, Nassim Taherian, Marielle Ruijs, Apollonia T. Helderman-van den Enden, Louise Izatt, Rosemarie Davidson, Muriel A. Adank, Lisa Walker, Rita Schmutzler, Kathy Tucker, Judy Kirk, Shirley Hodgson, Marion Harris, Fiona Douglas, Geoffrey J. Lindeman, Janez Zgajnar, Marc Tischkowitz, Virginia E. Clowes, Rachel Susman, Teresa Ramón y Cajal, Nicholas Patcher, Neus Gadea, Allan Spigelman, Theo van Os, Annelie Liljegren, Lucy Side, Carole Brewer, Angela F. Brady, Alan Donaldson, Vigdis Stefansdottir, Eitan Friedman, Rakefet Chen-Shtoyerman, David J. Amor, Lucia Copakova, Julian Barwell, Veda N. Giri, Vedang Murthy, Nicola Nicolai, Soo-Hwang Teo, Lynn Greenhalgh, Sara Strom, Alex Henderson, John McGrath, David Gallagher, Neil Aaronson, Audrey Ardern-Jones, Chris Bangma, David Dearnaley, Philandra Costello, Jorunn Eyfjord, Jeanette Rothwell, Alison Falconer, Henrik Gronberg, Freddie C. Hamdy, Oskar Johannsson, Vincent Khoo, Zsofia Kote-Jarai, Jan Lubinski, Ulrika Axcrona, Jane Melia, Joanne McKinley, Anita V. Mitra, Clare Moynihan, Gad Rennert, Mohnish Suri, Penny Wilson, Emma Killick, The IMPACT Collaborators, Sue Moss, Rosalind A. Eeles

Abstract

Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations.

X Demographics

X Demographics

The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 308 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
Australia 1 <1%
India 1 <1%
Ireland 1 <1%
Canada 1 <1%
Romania 1 <1%
Russia 1 <1%
United States 1 <1%
Unknown 299 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 55 18%
Student > Ph. D. Student 31 10%
Student > Bachelor 29 9%
Other 28 9%
Student > Master 23 7%
Other 71 23%
Unknown 71 23%
Readers by discipline Count As %
Medicine and Dentistry 131 43%
Biochemistry, Genetics and Molecular Biology 34 11%
Agricultural and Biological Sciences 30 10%
Nursing and Health Professions 5 2%
Business, Management and Accounting 3 <1%
Other 20 6%
Unknown 85 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 August 2017.
All research outputs
#1,974,460
of 26,017,215 outputs
Outputs from European Urology
#1,259
of 6,295 outputs
Outputs of similar age
#23,031
of 343,509 outputs
Outputs of similar age from European Urology
#11
of 139 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,295 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.2. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,509 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 139 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.